Endpoints News · Nov 2025
Described JAM-2 as a major step up in drug-like de novo antibody design, with better success rates, developability, and GPCR results.
We use AI to design antibodies for intractable diseases
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Nabla Bio is a Cambridge-based biotechnology company (founded in 2020, publicly launched in 2021) building JAM / JAM-2, a multimodal generative protein-design platform that combines AI with integrated wet-lab experimentation to design de novo antibodies and multispecific biologics for hard-to-drug targets, especially membrane proteins.
Primary product
JAM / JAM-2, a multimodal generative antibody design platform for de novo biologics design
Founded
2020
Headquarters
840 Memorial Dr, Riverside Technology Center, Cambridge, Massachusetts 02139, United States
Team size
11-50 employees
Work style
Onsite
Industry
Biotechnology
Sub-industry
AI drug discovery / antibody design
Open Positions
13 jobs at Nabla Bio
Lifecycle Marketing Manager
On-siteProductParis office4d ago
On-site